Last reviewed · How we verify
NCT06019325
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
NA trial testing RIB in Breast Cancer in 254 participants. Completed in 15 April 2025.
15 October 2024
Quick facts
| Lead sponsor | Muğla Sıtkı Koçman University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 254 |
| Start date | 7 September 2023 |
| Primary completion | 15 October 2024 |
| Estimated completion | 15 April 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- RIB
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Postoperative Pain, Acute — all drugs for Postoperative Pain, Acute →
- Postoperative Pain, Chronic — all drugs for Postoperative Pain, Chronic →
- Neuropathic Pain — all drugs for Neuropathic Pain →
Sponsor
Muğla Sıtkı Koçman University
Who can join
Adults 18 to 70, female only, with Breast Cancer or Postoperative Pain, Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rhomboid intercostal block is used to block lateral cutaneous branches of intercostal nerves between T3 and T9 dermatomes. RIB has been reported to be successful in attenuating acute pain following breast surgeries. However, it's effect on chronic pain has not been evaluated yet. The primary hypothesis of the study is that the incidence of chronic pain of the patients who will receive Rhomboid intercostal block (RIB) following breast cancer surgery will be lower than the patients who will receive no block intervention at the postoperative 3rd month. The secondary hypothesis is that the incidence ofchronic pain of the patients who will receive Rhomboid intercostal block (RIB) following breast cancer surgery will be lower than the patients who will receive no block intervention at the postoperative 6th month. An other secondary hypothesis is that the total BPI-SF scores will be lower in the RIB group than control group at the postoperative 3rd and the 6th months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06019325
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Muğla Sıtkı Koçman University trials
Trials by the same sponsor.
- NCT05046834 — Effect of Cold Application on Patient's Pain and Vital Signs During Chest Tube Removal. · NA · withdrawn
- NCT07323160 — Determining the Effect of Education Given to Patients Undergoing Outpatient Anal Fistula Surgery · NA · not yet recruiting
- NCT07308730 — Pain Diary Use After Laparoscopic Cholecystectomy · NA · recruiting
- NCT06704399 — Psychoeducation Based on Acceptance and Commitment Therapy · NA · not yet recruiting
- NCT07183956 — Comparison of the Silverman-Andersen Score and the Downes Score · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06019325 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Muğla Sıtkı Koçman University
- Last refreshed: 24 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06019325.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing